Placeholder Banner

BIO Comments: Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access

December 5, 2017

The Biotechnology Innovation Organization (“BIO”) welcomes the opportunity to submit written comments to supplement our previous live testimony to the FDA’s open docket on the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. BIO appreciated the opportunity to participate in FDA’s July 18th public meeting on this important topic and we are happy to supplement the record with these written comments. 

 

BIO also supplemted the comments we filed on September 19, 2017 to better inform the Docket on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. 1 Following submission of our comments pursuant to the initial closing date, other stakeholder comments were filed that raise issues of significant concern to BIO and our members. To ensure stakeholder interests in this issue are fully and accurately reflected, BIO submits these supplemental comments for FDA’s consideration

Download Full Comments Below
Comment From Biotechnology Innovation Organization BIO (1)
Bio Comments on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
Supplemental Comment From Biotechnology Innovation Organization BIO
Supplemental Comments: Bio Comments on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…